(19)
(11) EP 4 816 367 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24821722.6

(22) Date of filing: 26.11.2024
(51) International Patent Classification (IPC): 
C07D 405/14(2006.01)
A61P 35/00(2006.01)
 C07D 401/14(2006.01)
A61K 31/506(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 401/14; C07D 405/14; A61P 35/00
(86) International application number:
PCT/US2024/057574
(87) International publication number:
WO 2025/117616 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 27.11.2023 US 202363603095 P
18.12.2023 US 202363611727 P
11.03.2024 US 202463563922 P

(71) Applicant: Nikang Therapeutics, Inc.
Wilmington DE 19803 (US)

(72) Inventors:
  • YU, Zhiyong
    Wilmington, Delaware 19803 (US)
  • LOU, Yan
    Wilmington, Delaware 19803 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 AND CYCLIN-DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY